Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.2B | $-830M | $-1.2B | $20M | -79.5% | 6.7% | 43.5% |
| 2024 | $2.1B | $-481M | $-825M | $-67M | -32.2% | 23.5% | 2381.9% |
| 2023 | $1.7B | $170M | $-33M | $13M | -1.0% | 9.2% | 150.2% |
| 2022 | $1.6B | $242M | $-13M | $-161M | -0.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,563.10 | 1,707.20 | 2,107.62 | 2,248.05 |
| Operating Revenue | - | 1,563.10 | 1,707.20 | 2,107.62 | 2,248.05 |
| Cost Of Revenue | - | 693.72 | 716.42 | 926.87 | 902.79 |
| Gross Profit | - | 869.38 | 990.78 | 1,180.76 | 1,345.26 |
| Operating Expense | - | 960.04 | 1,039.15 | 1,284.18 | 1,364.13 |
| Research And Development | - | 60.83 | 75.33 | 91.30 | 120.33 |
| Selling General And Administration | - | 772.91 | 830.30 | 1,027.35 | 1,070.15 |
| Total Expenses | - | 1,653.76 | 1,755.57 | 2,211.05 | 2,266.92 |
| Operating Income | - | -90.66 | -48.37 | -103.43 | -18.87 |
| Total Operating Income As Reported | - | -71.18 | -65.71 | -775.72 | -1,124.23 |
| EBITDA | - | 241.69 | 169.73 | -481.03 | -830.22 |
| Normalized EBITDA | - | 131.14 | 194.40 | 191.26 | 275.14 |
| EBIT | - | 21.98 | -47.38 | -765.82 | -1,124.60 |
| Interest Expense | - | 24.05 | 19.75 | 57.10 | 34.82 |
| Net Interest Income | - | -24.05 | -19.75 | -57.10 | -34.82 |
| Other Non Operating Income Expenses | - | 2.09 | 25.66 | 9.90 | -0.37 |
| Other Income Expense | - | 112.64 | 1 | -662.40 | -1,105.73 |
| Interest Expense Non Operating | - | 24.05 | 19.75 | 57.10 | 34.82 |
| Net Non Operating Interest Income Expense | - | -24.05 | -19.75 | -57.10 | -34.82 |
| Pretax Income | - | -2.07 | -67.13 | -822.92 | -1,159.42 |
| Tax Provision | - | 36.12 | -13.29 | 4.49 | 22.29 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 23.22 | -4.88 | -141.18 | -232.13 |
| Net Income Continuous Operations | - | -38.19 | -53.84 | -827.42 | -1,181.71 |
| Net Income From Continuing And Discontinued Operation | - | -13.29 | -33.26 | -825.49 | -1,184.44 |
| Net Income From Continuing Operation Net Minority Interest | - | -39.72 | -54.37 | -828.10 | -1,182.53 |
| Net Income | - | -13.29 | -33.26 | -825.49 | -1,184.44 |
| Net Income Common Stockholders | - | -13.29 | -33.26 | -825.49 | -1,184.44 |
| Net Income Including Noncontrolling Interests | - | -11.76 | -32.73 | -824.82 | -1,183.62 |
| Normalized Income | - | -127.06 | -34.59 | -296.99 | -309.30 |
| Diluted NI Availto Com Stockholders | - | -13.29 | -33.26 | -825.49 | -1,184.44 |
| Basic Average Shares | - | 53.17 | 54.53 | 55.29 | 57.08 |
| Diluted Average Shares | - | 53.17 | 54.98 | 55.29 | 57.08 |
| Reconciled Depreciation | - | 219.71 | 217.11 | 284.80 | 294.38 |
| Reconciled Cost Of Revenue | - | 600.31 | 632.83 | 807.60 | 782.06 |
| Total Unusual Items | - | 110.55 | -24.67 | -672.29 | -1,105.36 |
| Total Unusual Items Excluding Goodwill | - | 110.55 | -24.67 | -672.29 | -1,105.36 |
| Minority Interests | - | -1.53 | -0.53 | -0.68 | -0.82 |
| Net Income Discontinuous Operations | - | 26.43 | 21.11 | 2.60 | -1.91 |
| Special Income Charges | - | -0.92 | -24.67 | -672.29 | -1,105.36 |
| Other Special Charges | 29.87 | -16.31 | 7.33 | - | 45.82 |
| Impairment Of Capital Assets | - | 0 | 0 | 645 | 1,049.75 |
| Restructuring And Mergern Acquisition | - | 17.23 | 17.34 | 27.29 | 9.79 |
| Gain On Sale Of Security | - | 111.47 | - | - | - |
| Depreciation Amortization Depletion Income Statement | - | 126.30 | 133.52 | 165.53 | 173.65 |
| Depreciation And Amortization In Income Statement | - | 126.30 | 133.52 | 165.53 | 173.65 |
| Amortization | - | 126.30 | 133.52 | 165.53 | 173.65 |
| Amortization Of Intangibles Income Statement | - | 126.30 | 133.52 | 165.53 | 173.65 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Enovis Corporationthis co. | ENOV | $1.3B | -1.11 | 0.88 | -79.5% | -3.20 |
| Bicara Therapeutics Inc. | BCAX | $1.3B | -9.72 | 3.34 | -34.4% | -8.01 |
| Inhibrx Biosciences, Inc. | INBX | $1.3B | -9.56 | 167.49 | -1752.2% | -10.54 |
| Ardelyx, Inc. | ARDX | $1.3B | -21.66 | 7.99 | -36.9% | -50.52 |
| Tandem Diabetes Care, Inc. | TNDM | $1.3B | -6.51 |
| - |
| - |
| - |
| - |
| - |
| 8.59 |
| -131.9% |
| -9.55 |
| AdaptHealth Corp. | AHCO | $1.3B | -18.70 | 0.87 | -4.7% | 6.60 |
| BioLife Solutions, Inc. | BLFS | $1.3B | -288.04 | 3.56 | -1.2% | -109.81 |
| Teladoc Health, Inc. | TDOC | $1.3B | -6.59 | 0.95 | -14.5% | 9.83 |
| Harrow, Inc. | HROW | $1.3B | -251.62 | 24.66 | -9.8% | 34.65 |
| Peer Median | - | -14.21 | 5.77 | -24.4% | -8.78 | |